87 results about "Dilated cardiomyopathy" patented technology

The invention provides a dilated cardiomyopathy zebrafish model and a construction method and application thereof, and belongs to the technical field of biology.The dilated cardiomyopathy zebrafish model is constructed by overexpressing miR-16-5p in myocardial cells of zebrafish, and the sequence of miR-16-5p is shown as SEQ ID NO.1; the invention further provides a construction method of the dilated cardiomyopathy zebra fish model. The invention constructs the dilated cardiomyopathy zebrafish model of overexpression miR-16-5p in myocardial cells for the first time, and the dilated cardiomyopathy zebrafish model can be used for screening drugs for resisting dilated cardiomyopathy.

The invention provides a construction method and application of a dilated cardiomyopathy animal model, belongs to the technical field of biological medicine and animal genetic model construction, and provides a novel dilated cardiomyopathy zebrafish model which is constructed by specifically overexpressing a truncated dnajb6b gene long isomer fragment in zebrafish myocardial cells. The nucleotide sequence of the gene segment is as shown in SEQ ID NO. 1; the invention also provides a construction method and application of the dilated cardiomyopathy zebra fish model, and further discovers application of 4-phenylbutyric acid in preparation of drugs for treating dilated cardiomyopathy.

The invention discloses a high-throughput screening method and a high-throughput screening system for a KLHL24 ubiquitin ligase inhibitor, which are high in stability and good in repeatability and are beneficial to efficient screening of the KLHL24 ubiquitin ligase inhibitor and development of related drugs. Based on the method, some KLHL24 ubiquitin ligase inhibitors are screened out, can be effectively used for treating diseases related to KLHL24, especially diseases caused by KLHL24 mutation, such as hereditary bullous epidermis, dilated cardiomyopathy, alopecia and atrophic scar, and have very good application prospects. In view of the function of KLHL24 in the aspect of skin and hair regeneration, the inhibitor also has a relatively good application prospect in the aspect of maintaining normal hair.

The present invention relates to use of expression vectors and other compounds in methods to disrupt the LInker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and / or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

The present disclosure relates to compositions and methods for the treatment of cardiomyopathy. Several embodiments provided for herein relate to virally-mediated transfer of a gene to host cells to induce expression of an encoded polypeptide, protein or other product to host in order to ameliorate one or more symptoms of the cardiomyopathy. In several embodiments, the methods and compositions relate to recombinant adeno-associated virus particles encoding human TNNT2 in order to treat cardiomyopathies, including dilated cardiomyopathy or hypertrophic cardiomyopathy.

The use of a bacterium of the species Lactobacillus salivarius in the manufacture of a food product, dietary supplement or medicament for treating cardiac dysfunction, particularly myocardial infarction, congestive heart failure, dilated cardiomyopathy or inflammatory heart disease (including endocarditis, inflammatory cardiomegaly and myocarditis) is disclosed.

The present invention provides novel 4-methylsulfone-substituted piperidine / urea compounds useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds, as well as methods for the treatment of DCM and other forms of heart disease, are described.

Synthetic nucleic acids encoding mini and microdystrophin genes comprising the membrane binding motifs or domains of the R10-R11-R12 region are provided. Also provided are vectors, host cells, and related methods of using the same to treat a subject suffering from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) or X-linked dilated cardiomyopathy (XLDC), or for ameliorating one or more adverse effects of DMD, BMD, or XLDC. Also provided are a fusion protein comprising a nNOS binding domain of dystrophin R16-R17 that is operably linked to a syntrophin PDZ domain and synthetic nucleic acids comprising the same that can be used to treat subjects with diseases characterized by loss of sarcolemmal neuronal nitric oxide synthase (nNOS) activity.

The present invention relates to use of expression vectors and other compounds in methods to disrupt the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and / or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

The application provides a method for constructing an animal model of dilated cardiomyopathy and application, belongs to the technical field of biological medicine and animal genetic model construction, provides a new zebrafish model of dilated cardiomyopathy, is constructed by specifically overexpressing a truncated dnajb6b gene long isoform fragment in zebrafish myocardial cells, the nucleotide sequence of the gene fragment is shown as SEQ ID NO. 1, and the method for constructing the zebrafish model of dilated cardiomyopathy and application are provided, and it is further found that 4-phenylbutyric acid is applied to the preparation of a drug for treating dilated cardiomyopathy.

The invention provides an LMNA mutant gene and application thereof, and belongs to the technical field of biomedicine. The nucleotide sequence of the human LMNA mutant gene is as shown in SEQ ID NO. 1. The LMNA mutant gene can be used for screening dilated cardiomyopathy and atrioventricular block and constructing a non-human animal model of the dilated cardiomyopathy and the atrioventricular block, and is beneficial to exploring pathophysiological processes of the dilated cardiomyopathy and the atrioventricular block and exploring therapeutic targets and drugs of the dilated cardiomyopathy and the atrioventricular block.

This application relates to the biomedical field and discloses a combination of biomarkers based on mitochondrial oxidative stress for the auxiliary diagnosis of dilated cardiomyopathy and its application. The biomarker combination includes the TARS2, NOX4, and SNCA genes. This biomarker combination can be used to prepare auxiliary diagnostic kits for dilated cardiomyopathy. By detecting the expression levels of each gene in the biomarker combination, the auxiliary diagnosis of dilated cardiomyopathy can be achieved efficiently and accurately. Compared with traditional diagnostic methods, this application, based on the characteristics of mitochondrial oxidative stress-related genes, has higher diagnostic accuracy and better applicability.

The invention discloses a processing method and device based on a heart three-dimensional image, equipment and a medium. The method comprises the following steps: acquiring a heart three-dimensional image and a chamber segmentation result to obtain a left ventricular heart cavity and a cardiac muscle; according to the inner diameter and the outer diameter of the myocardial, constructing a three-dimensional inner diameter curved surface and generating myocardial wall thickness mapping; determining a pre-trained classification model and constructing two-channel input of the classification model; inputting the curved surface and the mapping into a first channel of a model, and combining whole heart segmentation or original image data of a second channel; and processing dual-channel input through the model, and outputting a cardiomyopathy classification result. According to the method, a complete spatial form is reserved through the three-dimensional inner diameter curved surface and wall thickness mapping, and precise and robust classification of various cardiomyopathy such as hypertrophic cardiomyopathy and dilated cardiomyopathy is realized by combining dual-channel feature fusion and interactive calibration of a space guidance mask; the problems of efficiently and accurately extracting features from a complex three-dimensional heart image and automatically identifying diseases are solved.

The invention provides a dilated cardiomyopathy child death risk prediction method, system and device, and relates to the technical field of medical prediction models.The method comprises the steps that clinical data of a target dilated cardiomyopathy child patient are obtained and input into a pre-constructed nomogram prediction model, and death risk prediction results of the target dilated cardiomyopathy child patient at multiple time points in the future are output; the nomogram prediction model is constructed through independent prediction factors, the amino-terminal brain natriuretic peptide precursor level, the gender and the digoxin use condition which are determined through single-factor and multi-factor Cox regression analysis. According to the method, the nomogram prediction model is constructed by integrating the key clinical variables, accurate prediction and individualized treatment guidance of the dilated cardiomyopathy death risk of children are achieved, and the accuracy of clinical decision and the prognosis management effect are effectively improved.

The application provides an application of (R)-8-hydroxy-3,5,7-trimethylisochroman-1-one in preparation of an anti-dilated cardiomyopathy drug, belongs to the technical field of anti-dilated cardiomyopathy drugs, and discloses that the compound (R)-8-hydroxy-3,5,7-trimethylisochroman-1-one has an anti-dilated cardiomyopathy effect for the first time, and provides an experimental basis and a theoretical basis for development of a new drug for preventing or treating dilated cardiomyopathy.

Provided herein are compositions and methods for treating or preventing dilated cardiomyopathy (DCM) in a subject in need thereof, for example, through correcting one or more point mutations in the RBM20 locus using CRISPR-associated base editing. TIFF2025538153000011.tif56128

The application discloses a traditional Chinese medicine composition for treating dilated cardiomyopathy, relates to the field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for improving ventricular remodeling of a dilated cardiomyopathy patient, which is prepared from the following traditional Chinese medicines in parts by weight: radix astragali 60-90 parts, semen platycladi 15-30 parts, cortex mori 15-30 parts, ramulus cinnamomi 10-15 parts, zingiberis rhizoma siccum 10-15 parts, curcuma zedoaria 10-20 parts, cinnamomum cassia 6-10 parts and euonymus alatus 10-15 parts. The application has remarkable advantages in improving heart failure symptoms of the DCM patient, reversing ventricular remodeling, improving exercise tolerance, controlling arrhythmia and improving long-term prognosis of the patient.

The application belongs to the field of genetic engineering, and particularly relates to a polynucleotide construct capable of expressing LMNA and application thereof in preventing and treating DCM. The synthetic intron in the application comprises: I) a nucleotide sequence as shown in SEQ ID No. 8, II) a nucleotide sequence having at least one mutation in the 1-8th position of the sequence shown in SEQ ID No. 8, or a nucleotide sequence having at least 90% homology with the sequence shown in I) or II). By using the synthetic intron in the application, two proteins can be simultaneously expressed through alternative splicing, and the ratio of the two proteins or the expression of a single protein can be regulated through mutation of the splicing signal. Compared with the existing gene therapy method for dilated cardiomyopathy caused by LMNA mutation, the expression vector for simultaneously expressing Lamin A and Lamin C proteins in the application has stronger rescue effect.

The invention relates to the technical field of medicine, in particular to a composition containing an angiotensin II receptor blocker and application of the composition in heart disease dilation medicine. The composition comprises an angiotensin converting enzyme inhibitor and an angiotensin II receptor blocker, and a small dose of ACEI and a large dose of ARB are combined to be used for dilating the heart disease. The traditional Chinese medicine composition has excellent effects in the aspects of reducing the left ventricular end diastolic anterior-posterior diameter or left-right diameter, plasma brain natriuretic peptide precursor (NT-pro BNP) plasma level, pulmonary arterial pressure and left ventricular ejection fraction, does not influence the normal levels of physiological indexes such as blood potassium, serum creatinine, urea nitrogen, alanine aminotransferase (ALT) and asparaginic acid aminotransferase (AST), and can be used for preparing a medicine for treating the left ventricular end diastole. The medicine can be applied to heart disease dilation medicines.

This invention discloses a high-throughput screening method and system for KLHL24 ubiquitin ligase inhibitors. The method exhibits high stability and reproducibility, facilitating the efficient screening of KLHL24 ubiquitin ligase inhibitors and the development of related drugs. Based on the aforementioned method, this invention has screened several KLHL24 ubiquitin ligase inhibitors, which can be effectively used to treat KLHL24-related diseases, particularly those caused by KLHL24 mutations, such as hereditary epidermolysis bullosa, dilated cardiomyopathy, alopecia, and atrophic scarring, showing excellent application prospects. Given the function of KLHL24 in skin and hair regeneration, this inhibitor also shows good application potential in maintaining normal hair growth.

The invention provides a heart transplantation nutrition prognosis analysis system for a patient with dilated cardiomyopathy, three factors including prealbumin (PA), total bile acid (TBA) and NRS2002 score are incorporated into the analysis system, a corresponding algorithm is provided, and based on the algorithm, the optimal cutoff value of an undesirable outcome is predicted to be 0.121, the sensitivity is 72.9%, the specificity is 92.9%, and the area under a ROC curve (AUC) is 0.885 (95% CI: 0.802-0.967); when the absolute error of a calibration curve is 0.049, the HL goodness of fit test is equal to 6.134 (P is equal to 0.632 gt, 0.05), the net income threshold probability of DCA is 0.04-0.94, and the threshold probability of CIC is greater than 0.50, the prediction is highly consistent with the actual outcome. Meanwhile, the AUC value of the algorithm is obviously larger than that of other existing prediction methods, the algorithm can serve as a reliable tool for evaluating the postoperative adverse outcome risk of the patient in clinical practice, an important reference basis is provided for optimizing the individualized treatment strategy of the patient to be transplanted and perfecting the organ distribution scheme, and the accuracy and rationality of heart transplantation diagnosis and treatment can be improved.

The present invention provides novel polymorphs of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamide (I-491) that are useful for the treatment of cardiac disorders including systolic dysfunction, dilated cardiomyopathy (DCM), heart failure with reserved ejection fraction (HFrEF), and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the polymorphs is described, as well as methods for treating systolic dysfunction, DCM, HFrEF, and other forms of heart disease.

The application belongs to the technical field of molecular diagnosis, and particularly relates to extracellular vesicle lncRNA as a molecular marker for diagnosing heart failure combined with dilated cardiomyopathy. The molecular marker is NR_045681, and the specific nucleic acid sequence of the extracellular vesicle lncRNA is shown in SEQ ID NO. 5. The technical scheme provided by the application effectively improves the detection accuracy of heart failure combined with dilated cardiomyopathy. The P value of the combination of the molecular marker is less than 0.05, the |log fold change (FC)| is greater than 1, and the molecular marker has obvious differential expression relative to a healthy control group.

The present invention belongs to the field of molecular diagnostic technology, and specifically relates to an exosomal miRNA as a molecular marker for diagnosing dilated cardiomyopathy complicated with heart failure and its application; the exosomal miRNA is any one or a combination of two or more molecular markers selected from miR-423-5p, miR-148a-3p, miR-185-5p, miR-320a-3p, miR-22-3p, miR-148b-3p, let-7i-5p, miR-103a-3p, miR-21-5p, and let-7d-5p. The specific nucleic acid sequences of the exosomal miRNA are shown in SEQ NO.1-10. Preferably, the miRNA is miR-423-5p, miR-148a-3p, or miR-148b-3p. The technical solution provided by the present invention effectively improves the detection accuracy of dilated cardiomyopathy complicated with heart failure. The molecular marker |log(FC)| > 0.5, and there are significant differential expressions in patients with dilated cardiomyopathy complicated with heart failure compared with the healthy control group. In addition, the molecular combination of the three preferably selected miRNAs has better diagnostic efficacy than a single molecule and has certain clinical application value.

This invention discloses an intelligent terminal and early warning method for home management of dilated cardiomyopathy (DCM) in children, integrating multi-parameter monitoring, belonging to the field of intelligent health management technology. The method includes the following steps: establishing an electromagnetic event timeline in the home health monitoring environment; synchronously collecting and correlating electrocardiogram (ECG), blood oxygen saturation, and body movement signals according to a unified time reference to form an intelligent early warning baseline and generate a time anchor. This invention achieves synchronous correlation between multi-source physiological signals and interference by establishing an electromagnetic event timeline and time anchor, and dynamically rearranges sampling time to maintain signal continuity. Through a rhythmic breathing-type time control table and a dynamic interference isolation mechanism, the sampling rhythm is inversely coordinated with electromagnetic events, effectively improving the stability and accuracy of heart rhythm analysis and achieving intelligent early warning for dilated cardiomyopathy in children.

The invention belongs to the technical field of molecular diagnosis, and particularly relates to an extracellular vesicle lncRNA as a molecular marker for diagnosing dilated heart disease complicated with heart failure. The molecular marker is NR045681, and the specific nucleic acid sequence of the extracellular vesicle lncRNA is as shown in SEQ NO. 5. According to the technical scheme provided by the invention, the detection accuracy of the dilated heart disease combined with heart failure is effectively improved, the P value of the combination of the molecular markers is less than 0.05, the log fold change (FC) is greater than 1, and the molecular markers have obvious differential expression compared with a healthy control group.

A compound of Formula (I) is provided: (I) Salts and crystalline forms of the compound of Formula (I) are also provided. The compound of Formula (I) and crystalline forms thereof can be used for the treatment of several conditions linked to the inhibition of SGK-1, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia, ischemic injury, ischemic infarction, inflammatory and fibrotic diseases, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; cancer; epilepsy; Parkinson's disease; and Lafora disease.

Provided herein are methods of treating dystrophinopathies and associated conditions using LING complex inhibitors. In one embodiment, the dystrophinopathy is selected from Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and DMD-associated dilated cardiomyopathy (DCM). In another embodiment, the associated condition is a myopathy and / or muscular dystrophy. In a further embodiment, the LING complex inhibitor is a dominant negative SUN1 (DNSUN1) polypeptide.

The present disclosure provides veterinary formulations comprising rapamycin or rapalogs for administration to companion animals and methods of using the formulations to treat cardiac dysfunction, including hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, pressure-overload cardiac hypertrophy, cancer, effects of aging, inflammatory disease, and viral infection.

The present invention relates to genetic methods for altering gene expression in humans or animals. In particular, the present invention relates to increasing the expression of a TTN gene in a cell or tissue of an animal or human wherein at least one allele of said gene carries a mutation that results in a truncated myogiant protein product. Also provided are therapeutic treatments, pharmaceutical compositions, and methods of treatment utilizing such pharmaceutical compositions.